Skip to content

Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department

A Randomized Double Blinded Study Comparing Use of Prochlorperazine Versus Prochlorperazine and Ketorolac in the Treatment of Pediatric Migraine in the Emergency Department

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01534806
Enrollment
0
Registered
2012-02-17
Start date
2012-01-31
Completion date
Unknown
Last updated
2014-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

Migraine

Brief summary

The aim of this study is to evaluate whether the use of prochlorperazine and ketorolac in combination lead in a larger reduction in pain score compared to prochlorperazine alone when treating pediatric migraine in the Emergency Department (ED). Our hypothesis is that this combination of medications treats not only the pain but also the associated gastrointestinal symptoms of migraine. The main outcome of this study is the reduction in the patient's pain score at 60 minutes from administration of the study medications. Secondary outcomes include the number of patients achieving complete resolution of the headache while in the ED, the number of patients requiring additional treatment interventions by the treating physician, the number of patients with resolution of the associated symptoms like nausea, vomiting, photophobia and phonophobia, the recurrence of headache in the 48-72 hours after discharge, and side effects of the medications.

Interventions

DRUGKetorolac

Ketorolac(0.5mg/kg) IV push

DRUGPlacebo

Sodium Chloride 0.9% - 10 mL IV push

Sponsors

Akron Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
8 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. patient aged 8-18 years presenting to Akron Children's Hospital (ACH) ED with complaint of headache 2. patient has an established diagnosis of migraine without aura or as established by history meets the criteria for migraine headache as defined by the International Criteria for Headache Disorder -II in 2004 a. At least 5 episodes of headache b. The headache should last between 1-72 hours c. The headache should include two of the following: i. Unilateral location, though may be bifrontal or frontotemporal in location but should not be occipital ii. Pulsing quality iii. Moderate to severe pain iv. Aggravation by or causing avoidance of routine physical activity d. One of the following symptoms should accompany the headache i. Nausea or vomiting ii. Photophobia or phonophobia e. The headache should not be attributed to another disorder based on history, physical and/or laboratory information.

Exclusion criteria

1. Patients with a contraindication to receiving prochlorperazine, ketorolac, diphenhydramine, or naproxen 2. Patients unable to complete the pain scale. 3. Patients on medications that will have a drug-drug interaction with the study medication including prochlorperazine, ketorolac, diphenhydramine or naproxen. 4. Patients with any medical condition that may be contributing or associated with the current headache such as concussion or trauma 5. Female patients with a positive urine HCG point of care test 6. Patients with diagnosis of or suspected to have chronic daily headaches defined as a headache lasting at least 4 hours for more than 15 days a month for the past 3 months. 7. Patients who received prochlorperazine or ketorolac in the past 48 hours. 8. Patients who had previously been randomized in this study in the past 3 months.

Design outcomes

Primary

MeasureTime frame
Reduction in the patient's pain score at 60 minutes from administration of the study medications60 minutes from administration of the study medications

Secondary

MeasureTime frame
number of patients achieving complete resolution of the headache while in the emergency department.while in the emergency department, an expected average of 2 hours.
number of patients requiring additional treatment interventions by the treating physicianwhile in the emergency department, an expected average of 2 hours.
number of patients with resolution of the associated symptoms like nausea, vomiting, photophobia and phonophobiawhile in the emergency department, an expected average of 2 hours.
recurrence of headache48-72 hours after discharge
side effects of medications48-72 hours after discharge

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026